Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study

Hızal, MutluBilgin, BurakPaksoy, NailKılıçkap, SadettinAtcı, Muhammed MustafaKahraman, SedaKeskinkılıç, MerveBilgetekin, İremAyhan, MuratTural, DenizEren, ÖnderAkkoç Mustafayev, Fatma NihanYaman, ŞebnemTatlı, Ali MuratBayram, ErtuğrulKutlu, YasinErtürk, İsmailÖzcan, ErkanGülmez, AhmetKorkmaz, MustafaAkagündüz, BaranErdem, DilekAkın Telli, TuğbaAksoy, AsudeÜskent, Necdetİriağaç, YakupKöse Baytemür, NaziyetAydın, DinçerSakalar, TeomanArak, HaciSelçukbiricik, FatihErgün, YakupKorkmaz, TanerAk, NaziyeÜnal, ÇağlarAkdeniz, NadiyeÖzgün, Mehmet AlpaslanÖksüzoğlu, BernaYalçın, BülentÖztop, İlhanAlgın, EfnanSakin, AbdullahAydıner, AdnanYumuk, Perran FuldenŞendur, Mehmet Ali Nahit2022-07-292022-07-292022Hızal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S. ... Şendur, M. A. N. (2022). Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study. Future Oncology, 18(23), 2573-2582. https://doi.org/10.2217/fon-2022-00831479-66941744-8301https://doi.org/10.2217/fon-2022-0083https://hdl.handle.net/20.500.12511/9620Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who were treated with first-line alectinib in terms of ALK-tyrosine kinase inhibitors, regardless of previous chemotherapy. The co-primary end points were progression-free survival both for all patients and for the treatment-naive population. The secondary end points were overall response rate, overall survival, rate of CNS progression and safety. Results & conclusion: A total of 274 patients (n = 177 for treatment-naive patients) were enrolled in the study. The median progression-free survival was 26 and 28.8 months for all patients and the treatment-naive group, respectively. The overall response rate, CNS progression rate and 1-year overall survival ratio were 77.9, 12.4 and 77%. Alectinib is a highly effective therapy with a favorable safety profile.eninfo:eu-repo/semantics/closedAccessAlectinibALKFirst-LineNon-Small-Cell Lung CancerReal-WorldReal-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group studyArticle18232573258210.2217/fon-2022-0083Q30008145151000012-s2.0-8513415603335734870Q2